Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Licenses Cancer Dx Technology from Chronix

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has licensed from Chronix Biomedical the rights to technology for early detection of cancer.

The Salt Lake City-based molecular diagnostics developer said in a statement today that it has licensed rights to the technology in North America, South America, and Europe for early detection of breast, colon, and prostate cancers. It will pay San Jose, Calif.-based Chronix upfront fees, milestone payments, and royalties based on technical and commercial success of the products.

Chronix's technology uses disease-specific biomarkers based on DNA fragments from damaged and dying cells that circulate in the bloodstream and are applicable to a range of cancers and other diseases. According to Myriad, a study of 575 individuals that was presented at the American Society of Clinical Oncology showed that Chronix's technology had 92 percent sensitivity and 100 percent specificity in indicating the presence of prostate or breast cancer.

"The technology we have licensed from Chronix Biomedical has the potential to revolutionize the early detection of cancer through the analysis of unique DNA sequences in blood samples," Mark Capone, president of Myriad Genetic Laboratories, said. "This acquisition is consistent with our strategy to broaden our preventive care portfolio beyond predictive medicine products for women's health, and supply healthcare providers with enhanced tools to catch disease early, when it is most treatable."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.